Veronica Di Carlo

Trends in ovarian cancer net survival in a northeastern Brazilian state (1996–2017)

Ovarian cancer survival in low- and middle-income countries is lower than in high-income countries, due to disparities in healthcare access and socioeconomic factors. This study aimed to describe trends in ovarian cancer survival in Sergipe, Northeast Brazil, by histological group. We analysed data on 948 women aged 15-99 years diagnosed with a cancer of the ovary between 1996 and 2017, in Sergipe, Brazil. One- and five-year net survival were estimated by histological group and calendar periods of diagnosis (1996-1999, 2000-2004, 2005-2009, 2010-2014, 2015-2017) using the Pohar-Perme estimator. Survival estimates were age-standardised using International Cancer Survival Standard weights. Between 1996 and 2017, one-year and five-year net survival for ovarian cancer were 63.4 % and 37.4 %, respectively. Five-year net survival trends increased from 30.9 % (2000-2004) to 46.8 % (2015-2017). Epithelial type I tumours comprised roughly a quarter of cases, while type II tumours constituted over half. Both types exhibited similar one-year survival, ranging from 67 % to 68.5 % during 1996-2017. However, five-year net survival for type II tumours was remarkably lower at 32.5 %, compared to 52 % for type I tumours. Despite a minor improvement in five-year net survival over the 22 years, survival for women with ovarian cancer remains unfavourable, particularly for those diagnosed with Type II epithelial tumours, which have remarkably lower five-year survival than Type I.

Trends in 5-year net survival for women diagnosed with breast, cervical or ovarian cancer in Japan, 2000–14 (CONCORD-3)

Abstract Background Breast, cervical and ovarian cancers significantly affect young and middle-aged women, both physically and socially. However, relevant comprehensive stratified analyses are limited. Using Japanese data from CONCORD-3, a global cancer survival surveillance program, we analyzed long-term survival trends. Methods Data from 16 Japanese population-based cancer registries were analyzed for women diagnosed aged 15–99 years during 2000–2014 with a tumor originating in the breast, cervix uteri or ovaries. Follow-up was extended to five years post-diagnosis or until December 31st, 2014. In situ tumors and death-certificate-only registrations were excluded. Five-year net survival was estimated with the Pohar Perme estimator by calendar period of diagnosis, morphology and stage, and age-standardized with International Cancer Survival Standard weights. Results During 2000–2014, 5-year net survival improved for breast cancer from 85.9% (95% CI, 85.2–86.6%) to 89.4% (88.9–89.9%), for cervical cancer from 67.5% (66.3–68.7%) to 71.4% (70.4–72.3%), and for ovarian cancer from 35.5% (33.8–37.2%) to 46.3% (44.9–47.7%). Five-year survival for tumors diagnosed at a localized stage remained consistently high (>98% for breast cancer and > 90% for cervical cancer). Ovarian cancer survival varied greatly according to morphology. Conclusions Five-year net survival for women with cancers of the breast, cervix, and ovary) in Japan improved during 2000–2014, and remained at a globally high level throughout this period. These gains are probably attributable to earlier detection of breast and cervical cancers and advances in multimodal treatment for all cancers. Survival for distant-stage cervical and ovarian cancers remains a challenge, underscoring the need for enhanced screening and treatment strategies.